Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2014—With the recent acquisition by Nuclea Biotechnologies of Wilex (Oncogene Science), Nuclea will begin its foray into the GMP manufacturing and marketing of the FDA 510(k)-cleared HER2/neu blood test out of its facility in Cambridge, Mass. The test is available as an in vitro diagnostic in the U.S., Canada, and Europe (CE mark).
January 2014—Royal Philips received 510(k) clearance from the FDA to market its HER2/neu IHC Digital Manual Read product in the U.S.
January 2014—Rainbow Scientific is offering advanced research products for human mesenchymal stem cell (hMSC) and human embryonic stem cell (hESC) culture from Biological Industries.
January 2014—Enzo Life Sciences has expanded its portfolio of drug discovery platforms with the introduction of the new Leading Light Sclerostin-LRP Screening System. Developed to meet the market need for a simple, sensitive biochemical screening assay for detection of sclerostin inhibitors (antagonists of the Wnt signaling pathway), this kit is a drug discovery tool for detecting small molecule inhibitors that disrupt the interaction between SOST and LRP5.
January 2014—Diagnostic BioSystems introduces a new chromogen to its color spectrum, PermaRed/HRP. This HRP-based substrate/chromogen system produces a sharp, contrasting brick red color.
January 2014—TriLink BioTechnologies has signed a licensing agreement with Biofortuna for use of its CleanAmp dNTPs in Biofortuna’s freeze-drying (lyophilized) contract development and production service.
January 2014—The FDA has approved Hologic’s Aptima HPV 16 18/45 genotype assay for use on its fully automated Panther system. The Aptima HPV 16 18/45 genotype assay is performed using Hologic’s ThinPrep liquid cytology specimen and is intended to test specimens from women with Aptima HPV assay-positive results. The addition of HPV genotype 45 is designed to help identify more women at risk for adenocarcinoma, with minimal impact to colposcopy rates.
January 2014—Abbott received FDA approval to expand the use of its RealTime HCV and RealTime HBV assay to run on its m2000 RealTime System. The new mPlus makes it possible for laboratories of any size to perform molecular diagnostic tests for infectious disease detection and therapy monitoring. It also enhances the Abbott m2000’s flexibility and makes molecular testing easier and more efficient.
January 2014—Zenalux Biomedical has improved measurement reproducibility in its Zenascope system by adding pressure-sensing capability to its optical probe. The system now allows users to dial in a target pressure for each measurement via the user interface. After probe-to-tissue contact is made, the user interface monitors pressure feedback from the tip of the optical probe, facilitating data collection at the desired contact pressure.
January 2014—Ventana Medical Systems launched the Ventana Gram Staining Kit. Automated for use on the Ventana BenchMark Special Stains instrument, the kit aids pathologists in the most basic classification of bacteria into gram-positive and gram-negative bacteria in fixed tissue samples.
